Prenetics Global Limited (NASDAQ:PRE - Get Free Report) dropped 2.6% during trading on Monday . The company traded as low as $5.10 and last traded at $5.25. Approximately 8,525 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 17,120 shares. The stock had previously closed at $5.39.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $9.00 price target on shares of Prenetics Global in a research note on Thursday, January 16th.
Read Our Latest Analysis on PRE
Prenetics Global Stock Performance
The company has a market cap of $70.67 million, a P/E ratio of -1.45 and a beta of -0.26. The firm has a 50 day moving average price of $4.40 and a 200-day moving average price of $4.92.
Institutional Trading of Prenetics Global
A hedge fund recently raised its stake in Prenetics Global stock. Nomura Holdings Inc. lifted its stake in shares of Prenetics Global Limited (NASDAQ:PRE - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 333,528 shares of the company's stock after acquiring an additional 10,576 shares during the quarter. Nomura Holdings Inc. owned about 2.73% of Prenetics Global worth $1,307,000 as of its most recent filing with the SEC. Institutional investors own 25.01% of the company's stock.
About Prenetics Global
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
Featured Stories
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
